Clinical Trials


Broward Health's clinical trials program focuses on finding better ways to treat illnesses through a voluntary program between patients and their doctors. A clinical trial is a research study where individuals receive investigational treatments under the supervision of a physician and other research professionals.

Clinical Trials

Broward Health's clinical trials program focuses on finding better ways to treat illnesses through a voluntary program between patients and their doctors. A clinical trial is a research study where individuals receive investigational treatments under the supervision of a physician and other research professionals.

What Are Clinical Trials?

Broward Health has a variety of Active Adult and Pediatric Clinical Trials available on a continual basis, which may include medical research using investigational devices or participation in a clinical drug trial for the treatment of heart disease, cancer, HIV/AIDS, memory disorders, traumatic brain injury, and other diseases.

Clinical trials are studies in which people volunteer to take part in tests of new drugs or procedures. Doctors use clinical trials to develop new treatments for serious diseases, such as cancer. For those individuals who do participate in a clinical trial, they may have an opportunity to benefit from a new treatment that not might otherwise have been known. You may learn more about clinical trials by visiting ClinicalTrials.gov.

Current Studies at Broward Health

Clinical trials are studies in which people volunteer to take part in tests of new drugs or procedures. Doctors use clinical trials to develop new treatments for serious diseases, such as cancer or cardiovascular disease. You may learn more about clinical trials by visiting ClinicalTrials.gov

COVID-19 TRIALS

  • Adult COVID-19
    • Orpheris: Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Pharmocokinetics, and Efficacy of OP-101 (dendrimer n-acetyl-cysteine) in Patients with Severe Coronavirus Disease 2019 (COVID-19)
    • LSALT: AB002, Multi-center, Randomized, Double-blind, Placebo-controlled, Proof of Concept Study of LSALT Peptide as Prevention of Acute Respiratory Disease Syndrome (ARDS) and Acute Kidney Injury (AKI) in Patients Infeced with SARS-CoV-2 (COVID-19) (Pro00045596)
    • OSCAR: A Randomised, Placebo-controlled Study Evaluating the Efficacy and Safety of Otilimab IV in Patients with Severe Pulmonary COVID-19 Related Disease
  • NCI-COVID: 

PEDIATRIC CANCER TRIALS 

  • Leukemia
    • AAML1531: A Children’s Oncology Protocol for Phase III, Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
    • AALL1631: A Children’s Oncology Protocol for an International Phase III Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbone   
    • AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) 
    • AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND# 133494, NSC# 772518) for Newly Diagnosed High-risk B-ALL; Risk-Adapted Post-induction Therapy for High-risk B-ALL, Mixed Phenotype Acute Leukemia and Disseminated B-LLy
  • Neuroblastoma
    • ANBL00B1: A Children’s Oncology Group Protocol for Biomarkers in Tumor Tissue Samples from Patients with Newly Diangosed Neuroblastoma or Ganglioneuroblastoma
    • ANBL1232: A Children’s Oncology Group Protocol for Response and Biology-Based Risk Factor Guided Therapy in Treating Younger Patients with Non-High Risk Neuroblastoma
    • ALTE15N2: LEAHRN (Late Effects After High-risk Neuroblastoma) Study
  • Renal/Kidney
    • AREN03B2: A Children’s Oncology Group Protocol for Study of Kidney Tumors in Younger Patient 
    • AREN1721: A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy Versus Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma Across All Age Groups
  • Other
    • ALTE05N1: A Children’s Oncology Protocol for Long-Term Follow-Up of Patients Who Have Participated in COG Studies
    • APEC1621: A Children's Oncology Protocol for MATCH (Molecular Analysis for Therapy Choice) Examining Molecular Changes Using Genomic Sequencing Technologies in Refractory/Recurrent Tumors in Children and Adolescents
    • APEC1621C: A Children's Oncology Protocol for MATCH (Molecular Analysis for Therapy Choice) for the Screening of Children and Adolescents
    • AGCT1532: A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors 
    • APEC14B1: A Children’s Oncology Protocol for Project: EveryChild: A Registry, Eligibility Screening, Biology, and Outcome Study
    • APEC1621G: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations
    • APEC1621I: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alteractions in Cell Cycle Genes
    • AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin Versus Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
    • ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in patients with Intermediate Risk (IR) Rhabdomysoarcoma (RMS)
    • ADVL1622: Phase 2 Trial of XL 184 (Cabozantinib) an oral Small-Molecule Inhibitor of Multiple Kinases in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors 
    • ACCL10P1: Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
    • ALTE11C2: Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
    • A031102: A Randomized Phase III Trial Comparing Conventional-dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
    • ALTE1631: A Randomized Web-based Phsical Activity Intervention Among Children and Adolescents with Cancer
    • ALTE16C1: Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
    • DCP-001: Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

PEDIATRIC HIV DISEASE

  • HIV
    • IMPAACT P1115 V2.0: A Very Early Intensive Treatment of HIV-1 Infected Infants to Achieve HIV Remission: A Phase I/II Proff of Concept Study
    • PH100 SMARTT V5.0: PHACS 100: Surveillance Monitoring for ART Toxicities in HIV Uninfected Children Born to HIV Infected Women (SMARTT Study). Version Change Includes SMARTT Reference Cohort Sub Study and SMARTT Nutrition Sub Study
    • (TIES) Treating Infants Early Study: V5.0 8/24/2018

YOUTH AND YOUNG ADULT HIV DISEASE

  • HIV
    • PH300 AMP Up V1.0: PH300: A Multi-Center Study of the Pediatric HIV/AIDS Cohort Study (PHACS), Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up) Version 1.0      
    • IMPAACT 2017 V3.0: Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV Infected Children and Adolescents - MOCHA More Options for Children and Adolescents

ADULT CANCER RESEARCH TRIALS

  • Lung    
    • FDI-213: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation Small Cell Lung Cancer (PENDING)
  • Breast
    • Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
    • Alliance A011502: Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial       
    • SWOG S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic Her2+ Breast Cancer
    • SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
    • NRG-B004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer       
  • Gynecologic
    • GOG-3041/AstraZeneca: Randomized, Multicentre, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) (PENDING)
    • Merck 7902: Phase III Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001) (PENDING)
  • Prostate

    NRG-GU005: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer       

  • Colon 
    • Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined wtih Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
  • Head and Neck 
    • EA3161: Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced Intermediate Risk HPV Positive OPCA
  • MT Group: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (Specimen Trial)    
    • MTG-022: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
  • Leukemia 
    • Alliance A041702: Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 years of age) with Chronic Lymphocytic Leukemia (CLL) 
    • EA9161: Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphcytic Leukemia (CLL)
  • Anal 
    • EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
  • Screening 
    • EAY131: Molecular Analysis for Therapy Choice (MATCH)  
  •  Biospecimen Trials
    • Fujirebio FDI-209: A Prospective Longitudinal Collection of Peripheral Blood to Support the Validation of Biomarkers as an Aid in Monitoring Disease in Patients with All Stages of Lung Cancer 
    • NSU and Broward Health Collaboration: Tissue Samples and Nucleotide Excision Repair Capacity to Evaluate the Nucleotide Excision Repair (NER) Capacity of Non-Tumor Adjacent (NTA) Tissue

      SERATRIALS - 18004: A Multi-Center Study for the Collection of Biospeciments for Research; Surplus Surgical Tissues and Surplus/Non-Surplus Biofluids for In-Vitro Research       

CARDIOVASCULAR RESEARCH

  • LESS-VT: FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT (LESS-VT) Study
  • SOLVE CRT: Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients (SOLVE CRT)
  • CONNECT - HF: Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure
  • INTERRUPT AF: Prospective EvaluatIoN of Open IrrigaTEd Ablation CatheteRs with High ResolUtion MapPing to Treat Paroxysmal Atrial Fibrillation (INTERRUPT AF)
  • OPTION: Comparison of Anticoagulation with Left Atrial Appendage Closure after AF Ablation (OPTION S2239)

Contact Us

Email Icon Email: BHResearch@browardhealth.org

Phone Icon Phone: 954-712-2983

Find a Doctor

We can match you to a doctor based on your location, language preference, and more. The search results will provide more ways to narrow your search.

Available At